Clinical Trials

29 enrolled

Stomach Neoplasms

NCT05122091 2024-02-26

Fruquintinib Plus SOX as Neoadjuvant Therapy for Locally Advanced Gastric Adenocarcinoma

53 enrolled

Stomach Neoplasms

NCT05435313 2024-01-17

Fruquintinib Combined With Tislelizumab and HAIC in Patients With Advanced Colorectal Liver Metastases Cancer Who Failed Standard Therapy

39 enrolled

Colorectal Neoplasms

NCT05522738 2024-01-08

Safety and Efficacy of Fruquintinib+FOLFIRI in RAS-mutated Metastatic Colorectal Cancer

Phase 1/2 Unknown

46 enrolled

Colorectal Neoplasms

NCT05795296 2023-08-30

Efficacy and Safety of Fruquintinib With Sintilimab as First-line Therapy in Gastric Cancer

Stomach Neoplasms

NCT05993702 2023-08-15

TAS-102 in Combination With Regorafenib or Fruquintinib for Third-line and Above Advanced Colorectal Cancer

Unknown

45 enrolled

TAS 102

NCT05982834 2023-08-09

Disitamab Vedotin, Fruquintinib and Tislelizumab in Second-line Treatment for HER2-positive MGC

Phase 1/2 Unknown

43 enrolled

HER2-positive Gastric Cancer

NCT05971199 2023-08-02

Phase II Study of Fruquintinib Combined With Sintilimab and TACE for Inoperable Primary Hepatocellular Carcinoma

27 enrolled

Carcinoma, Hepatocellular

NCT05763927 2023-03-10

Neoadjuvant Therapy for Locally Advanced Rectal Cancer With Fruquintinib, Toripalimab and SRT

44 enrolled

Rectal Neoplasms

NCT05643677 2022-12-09

Fruquintinib Plus Irinotecan in the Treatment of Advanced Gastric Cancer

47 enrolled

Stomach Neoplasms

NCT05636150 2022-12-05

A Phase II Clinical Study of Fruquintinib Combined With S-1 for Advanced Esophageal Squamous Cell Carcinoma

48 enrolled

Esophageal Squamous Cell Carcinoma

NCT05634590 2022-12-02

The Efficacy and Safety of Fruquintinib Plus FOLFIRI/FOLFOX as Second-line Treatment in Patients With RAS-mutant Metastatic Colorectal Cancer

68 enrolled

Colorectal Neoplasms

NCT05635149 2022-12-02

Predictive Factors for Outcomes of Fruquintinib Plus Immunotherapy in Colorectal Cancer

Unknown

100 enrolled

Colorectal Adenocarcinoma

NCT05575635 2022-10-12

Neoadjuvant Treatment of Fruquintinib Combined With Concurrent Chemoradiotherapy for LARC

40 enrolled

Rectal Neoplasms

NCT05279677 2022-08-23

FMT Combined With Immune Checkpoint Inhibitor and TKI in the Treatment of CRC Patients With Advanced Stage

Colonic Neoplasms

NCT05511051 2022-08-22

A Prospective Multi-centered Randomized Controlled Trial on Fruquintinib in Combination With HAIC in the Treatment of Liver Metastatic Colorectal Cancer After Failure of Second-line Systematic Therapy

102 enrolled

Colorectal Neoplasms

NCT05004831 2022-08-18

Fruquintinib Combined With TAS-102 in the Treatment of Patients With Advanced Metastatic CRC

54 enrolled

Colorectal Neoplasms

NCT05016869 2022-08-18

Fruquintinib Plus Capecitabine as Maintenance Treatment of RAS / BRAF Wild-type Metastatic Colorectal Cancer

Phase 1/2 Unknown

48 enrolled

Colorectal Neoplasms

NCT04924179 2022-08-17

Tislelizumab Combined With Fruquintinib and SBRT as Athird-line and Posterior Line Treatment in Patients With Advanced CRC

25 enrolled

Patients With Advanced Metastatic Colorectal Cancer

NCT04733963 2022-07-26

Fruquintinib Plus Capecitabine Versus Bevacizumab Plus Capecitabine as Maintenance Therapy Following First-line Treatment for Metastatic Colorectal Cancer

112 enrolled

Colorectal Neoplasms

NCT04866862 2022-07-25

Fruquitinib Combined With Camrelizumab in Non MSI-H/dMMR Refractory Colorectal Cancer

32 enrolled

Colorectal Neoplasms

NCT05451719 2022-07-12

Fruquintinib Plus Capecitabine Versus Capecitabine as Maintenance Therapy for Metastatic Colorectal Cancer After First-line Chemotherapy

116 enrolled

Colorectal Neoplasms

NCT05447715 2022-07-07

Fruquintinib Sequential BEV+FOLFIRI vs. BEV+FOLFIRI Sequential Fruquintinib in Metastatic Colorectal Cancer

134 enrolled

Colorectal Neoplasms

NCT05406206 2022-06-06

Hepatic Arterial Infusion Chemotherapy With Fruquintinib for Colorectal Cancer Liver Metastases As Third-line Therapy

27 enrolled

Advanced Colorectal Carcinoma

NCT05292417 2022-03-31

Radiotherapy in Combination With Sintilimab，GM-CSF and Fruquintinib in Patients With MSS mCRC

71 enrolled

Colorectal Neoplasms

NCT05241899 2022-02-16

A Phase II Clinical Study of Fruquintinib Combined With RC48 in the Treatment of Previously Treated HER2-positive Locally Advanced or Metastatic Gastric or Gastroesophageal Junction (G/GEJ) Cancer

56 enrolled

Stomach Neoplasms

NCT05168527 2022-01-14

The First Line Treatment of Fruquintinib Combined With Albumin Paclitaxel and Gemcitabine in Pancreatic Cancer Patients

Pancreatic Neoplasms

NCT04582981 2021-10-26

Fruquintinib and Raltitrexed Versus Fruquintinib Monotherapy in Advanced Colorectal Cancer

136 enrolled

Advanced Colorectal Carcinoma

NCT04948034 2021-08-27

The Combination of Fruquintinib, Tislelizumab and Stereotactic Ablative Radiotherapy in Metastatic Colorectal Cancer(RIFLE)

68 enrolled

Colorectal Neoplasms

NCT04989855 2021-08-04

Fruquintinib Plus PD-1 Antibody in pMMR / MSS Locally Advanced Rectal Cancer (LARC) With High Immune Score

48 enrolled

Locally Advanced Rectal Cancer

NCT03977090 2021-02-10

Geptanolimab(GB226) Combined With Fruquintinib in the Treatment of Metastatic Colorectal Cancer

Phase 1 Unknown

21 enrolled

Colorectal Neoplasms

NCT04695470 2021-01-07

Phase II Trial of Fruquintinib With Sintilimab in Treating Selected Refractory Metastatic Colorectal Cancer Patients

70 enrolled

Colorectal Neoplasms

NCT04431791 2020-06-16

Real World Study of Regorafenib Versus Fruquintinib in Colorectal Cancer

Unknown

268 enrolled

Colorectal Neoplasms

NCT04179084 2019-11-26

Phase II Study to Evaluate the Efficacy and Safety of Fruquintinib Plus Sintilimab as Third-line Therapy for Colorectal Cancer

Metastasis Colorectal Cancer

NCT04156958 2019-11-08

FSTAMBTA

33 enrolled